EQS-News: Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board
|
EQS-News: Viromed Medical AG
/ Key word(s): Personnel
Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board Pinneberg, 3 December 2024 – The Supervisory Board of Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) has appointed Mr. Christian Strauch as a new member of the company's Management Board with effect from 1 January 2025. The previous sole member of the Management Board, Uwe Perbandt, has been appointed Chairman of the Management Board. "Viromed Medical AG is facing major challenges in the further research, application and global marketing of cold plasma technology. In order to meet these challenges efficiently and successfully, we need to spread the workload across a larger team. In Christian Strauch, we have found an outstanding and internationally experienced expert who, with his extensive know-how, can make a significant contribution to the success of the company," explained Dr. Jan Delphendahl, Chairman of the Supervisory Board of Viromed Medical AG. Christian Strauch has a degree in business administration ("Diplom-Kaufmann") and has many years of experience and a proven track record in building and expanding companies within the healthcare sector. He also has an international network of contacts with decision-makers in the development, manufacturing and distribution of healthcare products. His professional career includes, among other things, more than ten years as a member of the management board of the mail-order pharmacy apo-rot, where he ultimately held the position of managing director. He was also the founder of Linsentaxi GmbH and Pauls Praxis GmbH, as well as the founder and managing partner of pharmedix GmbH. Most recently, he was managing partner of Vameda GmbH, a holding company for corporate investments in the healthcare sector. Uwe Perbandt, former sole member of the Management Board of Viromed Medical AG, added: "I am very much looking forward to working with Christian Strauch in the future. With his experience and contacts, he will actively support and assist me in the next steps of Viromed's growth. This will enable me to focus more on my core competencies and together we can lead the company to success." About Viromed Medical AG: Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG is pursuing the goal of further advancing the use of CAP in medicine in the coming years and realizing the corresponding growth potential.
Contact Viromed Medical AG Uwe Perbandt
03.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Viromed Medical AG |
| Flensburger Straße 18 | |
| 25421 Pinneberg | |
| Germany | |
| Phone: | +49 4101 809960 |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A3MQR65 |
| WKN: | A3MQR6 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg |
| EQS News ID: | 2043367 |
| End of News | EQS News Service |
|
|
2043367 03.12.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | |
| Earnings per share8 | 0,00 | 0,00 | 0,00 | 1,23 | -0,01 | -0,01 | -0,02 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Bernd Lenzen
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Viromed Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3MQR6 | DE000A3MQR65 | AG | 55,08 Mio € | 04.05.2022 | 9F5FMQGX+GC | |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 68,00 | 0,00 | 0,00 | 136,00 | 2,76 | -500,73 | 0,00 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 19.08.2024 | 30.09.2024 | 12.07.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +25,87% | +0,00% | +0,00% | +0,00% | -43,33% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
